Quinapril

As a high-incidence chronic cardiovascular disease, hypertension is always treated with RAAS inhibitors as the first-line medication option in clinical practice. Quinapril is an angiotensin-converting enzyme (ACE) inhibitor. It reduces peripheral vascular resistance by blocking the conversion of angiotensin I to angiotensin II which has a vasoconstrictive effect, and reduces aldosterone secretion at the same time, so as to achieve the effect of stable blood pressure reduction. It can also improve ventricular remodeling in patients with congestive heart failure. Clinically, it is mainly used for the treatment of hypertension and congestive heart failure, applicable to monotherapy or combination therapy for adult hypertension patients, as well as long-term control of heart failure symptoms.

At present, the global quinapril market size maintains a steady growth trend. In 2023, the global market size was approximately USD 210 million, of which generic drugs accounted for more than 85%. In terms of the domestic market, with the expansion of the hypertension patient base and the increase of the penetration rate of primary-level medication, the annual compound growth rate of the quinapril preparation market in the past three years has remained at around 7.2%. Currently, the quinapril preparations marketed in China are mainly generic drugs, with a high concentration of market share among leading enterprises, and there is still certain room for domestic substitution on the API supply side.

The original developer of quinapril is Pfizer, with the original brand name Accupril. Its core compound patent in the United States expired in 2010, and its compound patent in China expired in 2009. The main dosage form approved for the original drug is tablet, with specifications including 5mg, 10mg, 20mg and 40mg. The original tablets have been included in the FDA Reference Listed Drug Catalog, and also included in China's *Catalog of Reference Preparations for Chemical Drugs*. Up to now, there are 4 quinapril API registration entries on the CDE API Registration Platform, 2 of which have been activated with A status, and a number of domestic enterprises have been approved to produce quinapril tablet preparations. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full range of quinapril impurity reference standards. Relevant products strictly meet the requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA. Most categories are in regular stock, and orders placed before 16:00 can be shipped on the same day, which can fully meet the reference substance use needs in API R&D, quality research and production links.